Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.
Back
Utilizing Clinical Pathways in Ovarian Cancer
Ryan Haumschild, PharmD, MS, MBA, provides insights surrounding the utilization of PARP inhibitors and clinical pathways in ovarian cancer treatment.
Utilizing Clinical Pathways in Ovarian Cancer
Episodes
All
All
Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.
The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.
Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.
Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.
Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.
A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.
In his closing thoughts, Dr Haumschild discusses unmet needs in the treatment landscape for ovarian cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists as the Glue in Cardio-Kidney-Metabolic Care
2
Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC
3
Pharmacists Can Close the LDL Control Gap in Lipid Care
4
Cancer Among 9/11 Survivors Is Accelerating 25 Years Later
5